IL161695A0 - Functional assay for agonist activation of receptors - Google Patents

Functional assay for agonist activation of receptors

Info

Publication number
IL161695A0
IL161695A0 IL16169502A IL16169502A IL161695A0 IL 161695 A0 IL161695 A0 IL 161695A0 IL 16169502 A IL16169502 A IL 16169502A IL 16169502 A IL16169502 A IL 16169502A IL 161695 A0 IL161695 A0 IL 161695A0
Authority
IL
Israel
Prior art keywords
receptors
functional assay
agonist activation
agonist
activation
Prior art date
Application number
IL16169502A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL161695A0 publication Critical patent/IL161695A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
IL16169502A 2001-11-09 2002-10-30 Functional assay for agonist activation of receptors IL161695A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34475501P 2001-11-09 2001-11-09
PCT/IB2002/004557 WO2003040303A2 (en) 2001-11-09 2002-10-30 Functional assay for agonist activation of receptors

Publications (1)

Publication Number Publication Date
IL161695A0 true IL161695A0 (en) 2004-09-27

Family

ID=23351886

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16169502A IL161695A0 (en) 2001-11-09 2002-10-30 Functional assay for agonist activation of receptors

Country Status (12)

Country Link
US (1) US20030104489A1 (xx)
EP (1) EP1310800A3 (xx)
JP (1) JP3676774B2 (xx)
KR (1) KR20040062623A (xx)
CN (1) CN1774630A (xx)
AU (1) AU2002350999A1 (xx)
CA (1) CA2411476A1 (xx)
HR (1) HRP20040407A2 (xx)
IL (1) IL161695A0 (xx)
NO (1) NO20041883L (xx)
RU (1) RU2004114213A (xx)
WO (1) WO2003040303A2 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421693D0 (en) 2004-09-30 2004-11-03 Amersham Biosciences Uk Ltd Method for measuring binding of a test compound to a G-protein coupled receptor
CN101063657A (zh) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 在活体细胞中筛选配体与受体结合的方法和系统
KR100852284B1 (ko) * 2006-07-07 2008-08-14 한국과학기술연구원 형광 이미징법을 이용한 ５－ｈｔ６ 수용체 리간드 고효율검색법
DE102007011913A1 (de) * 2007-03-13 2008-10-23 Sanofi-Aventis Fluoreszenz-basiertes Assay zum Erkennen von Verbindungen zum Modulieren des Natrium-Calcium-Austauschers (NCX) im "Vorwärtsmodus"
CA2785838C (en) 2009-12-29 2016-08-09 Suven Life Sciences Limited Functional assay for 5-ht2a receptor, histamine h1 receptor or adrenergic alpha 1b receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375390T1 (de) * 1999-10-29 2007-10-15 Pfizer G-protein-gekoppelter rezeptor-ähnliche proteine

Also Published As

Publication number Publication date
HRP20040407A2 (en) 2005-06-30
US20030104489A1 (en) 2003-06-05
JP2003194810A (ja) 2003-07-09
KR20040062623A (ko) 2004-07-07
WO2003040303A2 (en) 2003-05-15
AU2002350999A1 (en) 2003-05-19
WO2003040303A3 (en) 2003-10-09
EP1310800A2 (en) 2003-05-14
RU2004114213A (ru) 2005-03-20
EP1310800A3 (en) 2004-02-11
NO20041883L (no) 2004-06-01
JP3676774B2 (ja) 2005-07-27
CN1774630A (zh) 2006-05-17
CA2411476A1 (en) 2003-05-09

Similar Documents

Publication Publication Date Title
AU2002334733B2 (en) MCH receptors antagonists
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
GB0130199D0 (en) New nematode feeding assay
AUPR833401A0 (en) G protein-coupled receptor antagonists
AU2002367424A1 (en) Androgen receptor antagonists
HU0200264D0 (en) Estrogen agonists/antagonists for the treatment of certain cancers
EP1351933A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
IL157654A0 (en) Benzimidazole derivatives which modulate chemokine receptors
AU2003260072A8 (en) Antagonists of chemokine receptors
HRP20040407A2 (en) Functional assay for agonist activation of receptors
AU2001240097A1 (en) G protein-coupled receptors
IL162238A0 (en) Arylation of olefins
AU2002359524A1 (en) P2x7 receptor antagonists
IL163580A0 (en) Assay for anti-ingap antibodies
AU2001249922A1 (en) G protein-coupled receptors
AU2001250528A1 (en) Agonists/antagonists of the gpr56 receptor as appetite control agents
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
AU2003223329A8 (en) Antagonists of rf-amide neuropeptides
EP1424557A4 (en) USE OF A G-PROTEIN-COUPLED RECEPTOR PROTEIN
AU2002327615A1 (en) G-protein coupled receptors
AU2002254466A1 (en) G-protein coupled receptors
WO2002077001A9 (en) Novel receptors
IL158063A0 (en) Crf receptor antagonists
AU2002316366A1 (en) G-protein coupled receptors
AU2002366272A8 (en) Edg-receptor agonist for the treatment of hypertension